AI, HER2-Low, and the Future of Precision Oncology
MD Newsline
In this episode of MD Newsline, Dr Frederick Howard, breast oncologist at the University of Chicago and leader of a research group focused on AI-driven biomarker development, explores the rapidly evolving role of artificial intelligence in breast cancer care. Dr. Howard provides a comprehensive overview of how AI is being integrated into oncology—from radiographic imaging and digital pathology to clinical decision support and language models. He discusses both the promise and the practical challenges of deploying AI tools in real-world workflows, including validation standards, regulatory...
info_outline
Late-Stage Breast Cancer Diagnosis Among Black Women in the Mid-South
MD Newsline
In this episode of MD Newsline, Dr. Janeane N. Anderson, Assistant Professor at the University of Tennessee Health Science Center and breast cancer researcher, shares insights from the ACCESS Study—an innovative qualitative research initiative focused on understanding why Black women in the Mid-South region are disproportionately diagnosed with advanced-stage breast cancer. Dr. Anderson discusses structural barriers, community-based recruitment strategies, and the importance of centering lived experiences in oncology research. She also highlights the critical need for equitable research...
info_outline
Understanding Cancer Disparities, Mistrust, and Access to Care
MD Newsline
In this episode of MD Newsline, Dr. Jordonna Brown, a medical oncologist at Kings County Hospital in New York City, shares her frontline experience caring for patients in a safety-net hospital setting. Speaking from the San Antonio Breast Cancer Symposium (SABCS), Dr. Brown discusses cancer disparities, late-stage presentation, mistrust in the healthcare system, and the evolving landscape of breast cancer treatment. She offers a candid look at the social determinants of health shaping patient outcomes—from delayed screening and misconceptions about chemotherapy to barriers in long-term...
info_outline
Inflammation and Resistance in MDS & AML: Targeting the JAK-STAT Axis
MD Newsline
In this episode of MD Newsline, Dr. Theodoros Karantanos, Assistant Professor of Medical Oncology at the Johns Hopkins University Sidney Kimmel Cancer Center, discusses the emerging role of inflammatory signaling in high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Dr. Karantanos shares insights from his laboratory research exploring how inflammatory pathways—particularly interferon gamma and JAK-STAT signaling—contribute to treatment resistance, including resistance to venetoclax. He also highlights the impact of TP53 mutations, bone marrow microenvironment...
info_outline
Host Factors in Immunotherapy: How Sex, Aging, and Lifestyle Shape Cancer Outcomes
MD Newsline
In this episode of MD Newsline, Dr. Marco Ruella, Associate Professor of Medicine at the University of Pennsylvania and Scientific Director of the Lymphoma Program, joins us from the American Society of Hematology (ASH) meeting to discuss a paradigm-shifting topic: host factors in cancer immunotherapy. Dr. Ruella explores how biological sex, aging, chronic inflammation, obesity, exercise, and the microbiome influence responses to therapies such as checkpoint inhibitors and CAR T-cell therapy. The conversation highlights emerging data, translational research, and the growing need to...
info_outline
What’s Next for CAR-T Cells? In Vivo Design, Toxicity, and Persistence
MD Newsline
In this episode of MD Newsline, Dr. Dejah Blake, a fifth-year PhD candidate at Emory University, joins us from the American Society of Hematology (ASH) conference to discuss the rapidly evolving landscape of CAR T-cell therapy. Dejah shares insights into engineering next-generation CAR T cells, improving accessibility through in vivo manufacturing, and addressing diversity gaps in clinical research. From armored CARs to gene editing and humanized mouse models, this conversation explores how innovation and equity must move forward together in advancing cancer immunotherapy. Episode...
info_outline
The Psychology of Prevention: Behavioral Strategies for Better Health Outcomes
MD Newsline
In this episode of MD Newsline, behavioral scientist Dr. Josh Klapow, registered dietitian Kim Shapira, and health advocate Sishman Rimpson explore the powerful connection between psychology, nutrition, and long-term health outcomes. Together, they unpack how behavioral patterns, mindset, and sustainable lifestyle changes influence chronic disease prevention and patient adherence. The discussion highlights the real-world challenges patients face when attempting to modify diet, physical activity, and stress management—and how healthcare professionals can better support lasting change...
info_outline
Beyond Statins: Modern Cholesterol Care, Risk Assessment, and the Future of Lipid Therapy
MD Newsline
In this episode of MD Newsline, Dr. Amber Johnson, Assistant Professor of Medicine and General Cardiologist at the University of Chicago, provides an in-depth look at modern cholesterol management and cardiovascular risk reduction. She discusses evolving lipid guidelines, aggressive LDL-C targets, statin intolerance, and the growing role of non-statin therapies. Dr. Johnson also explores emerging research on lipoprotein(a), hypertriglyceridemia, and future directions in lipid-lowering treatment. Episode Highlights Evolving Cholesterol Management and ASCVD Risk Dr. Johnson explains how...
info_outline
Man Enough to Feel: Breaking the Stigma Around Men’s Mental Health
MD Newsline
In this episode of MD Newsline, a distinguished panel of physicians, mental health leaders, former professional athletes, and performance coaches come together for a powerful discussion on men’s mental health, vulnerability, and emotional wellbeing. The conversation explores how traditional definitions of masculinity impact mental health, performance, relationships, and help-seeking behaviors—and why redefining strength is critical for future generations. Panelists include Dr. Mike Banna, Dominique Easley, Jason Sousa, Dr. Nate Evans Jr., and Dr. Pete Thomas, each bringing unique...
info_outline
Understanding Alzheimer’s Disease: Biomarkers and Early Detection
MD Newsline
In this episode of MD Newsline, Dr. Rudolph J. Castellani, a neuropathologist and Director of the Division of Neuropathology at Northwestern University, offers a deep dive into the biology, diagnosis, and ongoing controversies surrounding Alzheimer’s disease. He explores how Alzheimer’s is defined clinically and pathologically, the evolving role of biomarkers in early detection, and why modifying biomarkers has not yet translated into meaningful clinical improvement for patients. Dr. Castellani also discusses the promise and limitations of artificial intelligence, personalized medicine,...
info_outlineIn this episode of MD Newsline, Dr. Gloria Dalla Costa, a researcher at Harvard University, shares groundbreaking insights into the role of ultra-processed foods in multiple sclerosis (MS) progression. Drawing from her research on environmental and metabolic risk factors, Dr. Dalla Costa discusses how dietary habits may influence inflammation, disease activity, and long-term neurological outcomes in MS patients.
Her work reveals compelling evidence that higher consumption of ultra-processed foods correlates with increased inflammatory markers, worsened MRI outcomes, and a greater risk of relapse. By analyzing blood-based metabolic signatures, her team is uncovering how these foods interact with biological pathways tied to chronic inflammation and neurodegeneration.
Dr. Dalla Costa also discusses the Nova classification of processed foods, the role of ceramides and other metabolites in cellular health, and how regional dietary patterns affect disease outcomes. She emphasizes the importance of adopting a Mediterranean-style diet and reducing ultra-processed food intake as a modifiable lifestyle factor that can complement established MS therapies.
Episode Highlights
Exploring Environmental Risk Factors for MS
Dr. Dalla Costa explains how her team investigates multiple environmental contributors to MS, including Epstein–Barr virus exposure, vitamin D levels, and now, ultra-processed food intake.
Ultra-Processed Foods and Disease Activity
Her findings show that MS patients with higher levels of ultra-processed food metabolites in their blood experience 30% more relapses and worse MRI lesion progression over five years.
Metabolic Signatures and Biomarkers
Dr. Dalla Costa outlines how measuring circulating metabolites in blood and urine offers an innovative way to assess dietary exposure objectively, bypassing unreliable food questionnaires.
Dietary Classification and Health Impact
The Nova system distinguishes between unprocessed, minimally processed, processed, and ultra-processed foods. Additives, preservatives, and colorants—while convenient—are linked to inflammation and metabolic stress.
Towards Personalized Nutrition in MS
Emerging evidence suggests that dietary modification could become a complementary approach in MS management. Dr. Dalla Costa envisions a future where AI and machine learning will personalize nutritional recommendations for patients.
Future Directions in Research
Her team plans to explore how ultra-processed foods affect the gut barrier, contribute to chronic inflammation, and potentially inform dietary policy and patient education globally.
Key Takeaway
Dr. Dalla Costa underscores that reducing ultra-processed food intake may serve as a simple yet powerful tool to support neurological health in MS patients. By combining validated therapies with mindful dietary choices, clinicians and patients can work together to mitigate inflammation and improve long-term outcomes.
Resources
Website: https://mdnewsline.com/
Newsletter: https://mdnewsline.com/subscribe/
Connect with Dr. Gloria Dalla Costa: Here